Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy
The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy|
- increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline [ Time Frame: 3 days ] [ Designated as safety issue: No ]samples will be collected at 24, 48 and 72 hours after PCI
- a 25% increase in SCr from baseline [ Time Frame: 3 days ] [ Designated as safety issue: No ]samples will be collected at 24, 48 and 72 hours after PCI.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||April 2010|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
|Patients underging PCI|
Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372891
|Contact: Ling Tao, M.D Ph.Demail@example.com|
|Xi'an, Shaanxi, China, 710032|
|Contact: Ling Tao, M.D Ph.D +86-15002955798 firstname.lastname@example.org|
|Principal Investigator: Ling Tao, M.D Ph.D|